文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

临床衰弱量表(CFS)判定的衰弱与COVID-19患者院内及30天死亡率升高相关:系统评价与Meta分析

Clinical Frailty Scale (CFS) indicated frailty is associated with increased in-hospital and 30-day mortality in COVID-19 patients: a systematic review and meta-analysis.
PubMed 文献 · Ann Intensive Care · 2022-02-20
一句话结论系统评价与Meta分析显示,CFS 4-9判定的衰弱与COVID-19患者死亡风险升高相关(OR 3.12,95%CI 2.56-3.81),且衰弱患者入住ICU的可能性更低(OR 0.28)。

该系统评价与Meta分析检索5个数据库至2021年9月24日,从3640条记录中纳入54项定性合成研究、42项定量合成研究,评估衰弱工具对COVID-19患者风险分层的价值。主要结局为死亡、住院时长和ICU入住。CFS 4-9或HFRS≥5的衰弱患者死亡风险更高(CFS:OR 3.12,95%CI 2.56-3.81;HFRS:OR 1.98,95%CI 1.89-2.07);CFS 4-9的衰弱患者入住ICU的可能性更低(OR 0.28,95%CI 0.12-0.64)。住院时长未能进行定量合成。多数研究存在高偏倚风险。作者认为基于衰弱的患者管理应纳入国际COVID-19治疗指南,并强烈呼吁未来研究探讨衰弱评估在决定ICU入住中的作用。

要点

  • CFS 4-9判定的衰弱与COVID-19患者死亡风险升高相关:OR 3.12(95%CI 2.56-3.81)。
  • HFRS≥5判定的衰弱同样与死亡风险升高相关:OR 1.98(95%CI 1.89-2.07)。
  • CFS 4-9的衰弱患者入住ICU的可能性更低:OR 0.28(95%CI 0.12-0.64)。
  • 住院时长未能进行定量合成,原文未报告相关合并效应量。
  • 多数纳入研究存在高偏倚风险,作者呼吁未来研究探讨衰弱评估对ICU入住决策的作用。

适用人群与场景

  • COVID-19患者,纳入报告衰弱情况的研究;各研究的具体纳入与排除标准原文未逐项列出。

诊断标准与关键阈值

  • 衰弱判定:临床衰弱量表(CFS)4-9分;医院衰弱风险评分(HFRS)≥5分。
  • CFS用于46项研究,HFRS用于4项研究,多维预后指数(MPI)用于3项研究,其他评分用于3项研究。

研究设计与关键结果

  • 研究类型:系统评价与Meta分析,方案注册号CRD42021241544,检索5个数据库至2021年9月24日,从3640条记录中纳入54项定性合成研究、42项定量合成研究。
  • 衰弱(CFS 4-9)患者死亡风险更高:OR 3.12(95%CI 2.56-3.81);衰弱(HFRS≥5)患者死亡风险更高:OR 1.98(95%CI 1.89-2.07)。
  • 衰弱(CFS 4-9)患者入住ICU的可能性更低:OR 0.28(95%CI 0.12-0.64)。
  • 住院时长(LOH)未能进行定量合成。
  • 使用随机效应模型计算OR和加权均数差(WMD)及95%CI,采用I²和χ²检验评估异质性,采用QUIPS工具评估偏倚风险。

证据类型、等级与局限

  • 证据类型:系统评价与Meta分析;采用QUIPS工具评估偏倚风险,未报告证据等级或推荐强度。
  • 局限:多数研究存在高偏倚风险。
  • 作者结论:未来研究探讨衰弱评估在决定ICU入住中的作用被强烈呼吁(strongly warranted)。

对床旁实践的改变

  • 作者认为,基于衰弱的患者管理应纳入国际COVID-19治疗指南。
  • 作者强烈呼吁未来研究探讨衰弱评估在决定ICU入住中的作用。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The concept of frailty provides an age-independent, easy-to-use tool for risk stratification. We aimed to summarize the evidence on the efficacy of frailty tools in risk assessment in COVID-19 patients.

METHODS: The protocol was registered (CRD42021241544). Studies reporting on frailty in COVID-19 patients were eligible. The main outcomes were mortality, length of hospital stay (LOH) and intensive care unit (ICU) admission in frail and non-frail COVID-19 patients. Frailty was also compared in survivors and non-survivors. Five databases were searched up to 24th September 2021. The QUIPS tool was used for the risk of bias assessment. Odds ratios (OR) and weighted mean differences (WMD) were calculated with 95% confidence intervals (CI) using a random effect model. Heterogeneity was assessed using the I2 and χ2 tests.

RESULTS: From 3640 records identified, 54 were included in the qualitative and 42 in the quantitative synthesis. Clinical Frailty Scale (CFS) was used in 46 studies, the Hospital Frailty Risk Score (HFRS) by 4, the Multidimensional Prognostic Index (MPI) by 3 and three studies used other scores. We found that patients with frailty (CFS 4-9 or HFRS ≥ 5) have a higher risk of mortality (CFS: OR: 3.12; CI 2.56-3.81; HFRS OR: 1.98; CI 1.89-2.07). Patients with frailty (CFS 4-9) were less likely to be admitted to ICU (OR 0.28, CI 0.12-0.64). Quantitative synthesis for LOH was not feasible. Most studies carried a high risk of bias.

CONCLUSIONS: As determined by CFS, frailty is strongly associated with mortality; hence, frailty-based patient management should be included in international COVID-19 treatment guidelines. Future studies investigating the role of frailty assessment on deciding ICU admission are strongly warranted.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Rottler M, Ocskay K, Sipos Z, et al. Clinical Frailty Scale (CFS) indicated frailty is associated with increased in-hospital and 30-day mortality in COVID-19 patients: a systematic review and meta-analysis. Ann Intensive Care. 2022. PMID: 35184215. doi:10.1186/s13613-021-00977-4

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。